Lisata Therapeutics, Inc.

What they do

Lisata is a clinical-stage company focused on discovering and developing therapies for solid tumors. Its lead product candidate, certepetide (formerly LSTA1/CEND-1), is designed to activate the C-end rule active transport mechanism to help co-administered anti-cancer drugs better penetrate tumors. Certepetide has been studied in Phase 2 trials for various cancers, including pancreatic, cholangiocarcinoma, appendiceal, colon, and glioblastoma, and is being evaluated in combinations with chemotherapies and immunotherapies.

Revenue drivers

• Licensing and collaboration revenue — The company reported $170,000 in total revenue for 2025 and $1.0 million in 2024, indicating intermittent licensing or collaboration income; no product sales exist.
• Other income from terminated merger — Received $1.0 million from Kuva Labs related to the terminated merger agreement in 2026; not a recurring revenue source.

Recent performance

For 2025, Lisata reported a net loss of $16.6 million and no quarterly revenue for most periods, with only $100,000 in Q4 2025. Operating cash flow was negative $15.9 million in 2025, a slight improvement from $19.4 million in 2024. As of June 30, 2026, cash and equivalents were $10.4 million, with total assets of $11.0 million and no long-term debt. The company terminated its merger agreement with Kuva Labs on July 24, 2026, after Kuva failed to secure financing, triggering a $2.0 million termination fee obligation.

Strategy

Lisata's strategy centers on advancing certepetide through global Phase 2 clinical trials for multiple solid tumor indications, including mPDAC and glioblastoma. The company is also generating preclinical data on certepetide with antibody drug conjugates (ADCs) through its research collaboration with Catalent, with data presented in Q4 2025. Management is focused on securing additional capital or strategic partnerships to fund operations and clinical development, especially after the failed merger. They are also pursuing legal remedies against Kuva Labs for damages and enforcement costs.

Risks

• Going concern risk — The company has recurring net losses and negative operating cash flow, with only $10.4 million in cash, which may not be sufficient to fund operations into the near term.
• Clinical development risk — Certepetide is in investigational stages; failure in ongoing or future Phase 2 trials would materially harm the business.
• Merger termination risk — Termination of the Kuva merger left the company without a buyer and may result in legal disputes and diversion of resources.
• Financing risk — Without product revenue, the company depends on external financing; inability to raise capital could force it to curtail operations.

Outlook

Management highlights the need to obtain sufficient capital or strategic arrangements to continue operations and advance clinical trials. They are pursuing legal remedies following the merger termination, including seeking damages and enforcement costs. The near-term outlook focuses on progressing certepetide's clinical programs while securing funding to sustain operations.